• DiaMedica flagged an FDA request for additional nonclinical reproductive-toxicity support for DM199 in preeclampsia, a key step toward a U.S. IND.
• FDA feedback indicated a prior rat reproductive-toxicity study could be acceptable if drug exposure and enzymatic activity are demonstrated across the study.
• The company plans a rat pharmacokinetic and activity study, then intends to resubmit the requested package to the FDA for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606160830BIZWIRE_USPR_____20260616_BW162333) on June 16, 2026, and is solely responsible for the information contained therein.